Exhibit 99.1

(ADEZA LOGO)

     
COMPANY CONTACT:
  INVESTOR CONTACTS:
Mark Fischer-Colbrie
  Jody Cain (jcain@lhai.com)
Chief Financial Officer
  Bruce Voss (bvoss@lhai.com)
Adeza Biomedical Corporation
  Lippert/Heilshorn & Associates, Inc.
(408) 745-0975
  (310) 691-7100
ir@adeza.com
   

ADEZA ANNOUNCES 2004 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Reports 10th Consecutive Quarter of Profitability on Record Product Sales

SUNNYVALE, Calif. (March 9, 2005)

– Adeza (NASDAQ: ADZA) today announced financial results for the three months and year ended December 31, 2004.

For the three months ended December 31, 2004, Adeza posted its 10th consecutive profitable quarter. The company reported that net income for the fourth quarter of 2004 was $1.6 million, an increase of $436,000 or 38% from net income of $1.2 million for the fourth quarter of 2003. Diluted net income per share for the fourth quarter of 2004 was $0.11 based on 14.5 million shares outstanding, compared with diluted net income per share of $0.09 based on 12.8 million shares outstanding for the fourth quarter of 2003. The change in share count is primarily attributed to the completion in December 2004 of the company’s initial public offering of 4.3 million common shares.

Adeza reported record quarterly product sales for the fourth quarter of 2004 of $9.2 million, an increase of $1.9 million or 26%, compared with product sales of $7.3 million for the fourth quarter of 2003. The increase in the 2004 fourth quarter is primarily attributed to higher unit sales of the Fetal Fibronectin Test.

For the three months ended December 31, 2004, selling and marketing expenses were $4.3 million, compared with $3.2 million for the comparable period in 2003, due mainly to additional field sales representatives, costs associated with increased headcount and expansion of marketing programs. General and administrative expenses for the fourth quarter of 2004 were $1.4 million, compared with $940,000 in the prior-year fourth quarter, due primarily to headcount related costs. Research and development expenses increased to $697,000 for the fourth quarter of 2004, compared with $481,000 for the fourth quarter of 2003, due mainly to costs related to clinical studies.

For the year ended December 31, 2004, Adeza reported net income of $8.9 million, or $0.65 per diluted share based on 13.6 million shares outstanding, compared with net income of $3.2 million, or $0.26 per diluted share based on 12.5 million shares outstanding, for the year ended December 31, 2003. Cost of product sales for 2004 included a one-time benefit of $2.7 million.

For the year ended December 31, 2004, the company reported product sales of $33.6 million, an increase of $7.1 million from $26.5 million for the year ended December 31, 2003.

As of December 31, 2004, Adeza had cash and cash equivalents of $80.1 million, stockholders’ equity of $81.7 million and working capital of $81.3 million. The company’s cash position as of December 31, 2004 reflects net proceeds of $61.9 million from the company’s initial public offering.

 


The following information was filed by Adeza Biomedical Corp on Wednesday, March 9, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adeza Biomedical Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adeza Biomedical Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account